Evidence map›Paper›PMID 42862489›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026

Novel insights on carbon source influence on azomycin production by Streptomyces eurocidicus.

Julia de Macedo Robert, Wagner Lopes, Alexandre Andrade de Souza Costa, Otavio Padula de Miranda, Tatiane Aparecida Nascimento, Maria da Conceição Avelino Dias, Filipe Soares Quirino da Silva, Fabius Vieira Leineweber, Graziela Jardim Pacheco

Abstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julia de Macedo RobertBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil. julia.robert@fiocruz.br.ORCID http://orcid.org/0000-0003-1945-4750
Wagner LopesBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Alexandre Andrade de Souza CostaBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Otavio Padula de MirandaBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Tatiane Aparecida NascimentoIntegrated Laboratory of Simuliids and Onchocerciasis & Medical and Forensic, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Maria da Conceição Avelino DiasDrug Synthesis Laboratory - Pharmacokinetics Unit, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Filipe Soares Quirino da SilvaDrug Synthesis Laboratory - Pharmacokinetics Unit, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Fabius Vieira LeineweberBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil.
Graziela Jardim PachecoBioprocess Laboratory, Institute of Drug Technology, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro, Brazil. graziela.pacheco@fiocruz.br.ORCID http://orcid.org/0000-0002-7493-7969

Funding

Fundação Oswaldo Cruz VPPIS-0004-FIO-22
6 · The paper itself

Abstract

Azomycin (2-nitroimidazole), a compound synthesized by Streptomyces eurocidicus, is medically significant as a build block for the drug applied in treatment for drug-resistant tuberculosis and Chagas disease, as well as tumor hypoxia imaging. Despite its clinical value, the optimized bioprocess parameters for its production remain largely unexplored. This study evaluated the influence of various carbon and nitrogen sources (specifically glucose, starch, soybean oil, and casamino acids) on azomycin yields during submerged cultivation. Batch fermentations revealed that azomycin biosynthesis is phase-shifted, initiating only after the primary carbon source is near depletion. Notably, although soybean oil served as an excellent carbon source for biomass accumulation, it yielded no detectable azomycin production. By contrast, supplementing the media with free amino acids (casamino acids) substantially enhanced product synthesis. Using an optimized semi-defined medium of glucose and casamino acids, a titer of 46.34 mg/L was achieved in 250 mL DASbox system. Scaling this configuration to an instrumented 3 L bioreactor resulted in a final concentration of 69.18 mg/L over 7 days, marking an 89% increase in the product-to-biomass yield (Yp/x) compared to the smaller scale tested. Liquid chromatography-mass spectrometry (LC-MS) verified the identity of the extracted 2-nitroimidazole. These findings demonstrate that the precision balancing of glucose and organic nitrogen is essential to unlock and maximize the biosynthetic potential of wild-type S. eurocidicus.

Indexed as

Anti-Bacterial AgentsCarbonNitroimidazolesStreptomycesAmino AcidsBiomassBioreactorsCulture MediaFermentationGlucoseNitrogenAmino AcidsAnti-Bacterial AgentsCarbonCulture MediaGlucoseNitrogenNitroimidazolesAntibioticAzomycinFermentationMixed substratesNatural productsStreptomyces

Identifiers

PMID42862489
PMCPMC13658643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.